64 Results for "

eIF4E

" in MedChemExpress (MCE) Product Catalog:
Products (64)

64 Results for "eIF4E" in MCE Product Catalog:

17
17 Publications Verification
Cat. No.: HY-19831
CAS No.: 315706-13-9
4EGI-1 is an inhibitor of eIF4E/eIF4G interaction, with a Kd of 25 μM against eIF4E binding.
15
15 Cited Publications
Cat. No.: HY-100022
CAS No.: 1849590-01-7
Purity:  99.92%
Synonyms: eFT508
Target:  

MNK PD-1/PD-L1

Research Areas:  

Cancer

Tomivosertib (eFT508) is a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib (eFT508) treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines . Tomivosertib (eFT508) also dramatically downregulates PD-L1 protein abundance .
5
5 Cited Publications
Cat. No.: HY-100733
CAS No.: 432499-63-3
Purity:  ≥98.0%
4E2RCat is an inhibitor of eIF4E-eIF4G interaction with an IC50 of 13.5 μM.
3
3 Cited Publications
Cat. No.: HY-14427
CAS No.: 328998-25-0
Purity:  98.89%
Research Areas:  

Cancer

4E1RCat is an inhibitor of cap-dependent translation, and inhibits eIF4E:eIF4GI interaction, with an IC50 an of ~4 μM.
1
1 Cited Publications
Cat. No.: HY-148105
CAS No.: 2373065-59-7
Purity:  99.10%
DS12881479 is a selective non-ATP-competitive MNK1 inhibitor with an IC50 value of 387 nM. DS12881479 stabilizes MNK1 in its autoinhibited DFD-out conformation, blocks eIF4E phosphorylation, suppresses tumor cell proliferation and induces weak apoptosis. DS12881479 also inhibits FLT3 and DYRK1a kinase activity at high concentrations. DS12881479 can be used for the research of cancer, such as leukemia .
Cat. No.: HY-145974A
CAS No.: 3080642-79-8
Purity:  99.40%
Synonyms: m7G(5')ppp(5')(2'OMeA)pG ammonium
m7GpppAmpG ammonium (m7G(5')ppp(5')(2'OMeA)pG ammonium) is a trinucleotide 5′ end cap analog. m7GpppAmpG ammonium binds to eIF4E with a KD value of 45.6 nM. m7GpppAmpG ammonium caps RNA with a capping efficiency of 90%. m7GpppAmpG ammonium enhances mRNA stability and translation efficiency. m7GpppAmpG ammonium is used in mRNA therapeutic research .
Cat. No.: HY-145262
CAS No.: 2575840-38-7
Purity:  98.76%
Research Areas:  

Cancer

eIF4E-IN-2 is a potent inhibitor of eukaryotic initiation factor 4e (eIF4e) with an IC50 of 13 nM. eIF4E-IN-2 inhibits MDA-MB-361 cells proliferation. eIF4E-IN-2 can be used for the study of breast cancer .
Cat. No.: HY-16366
CAS No.: 865783-99-9
Synonyms: ON 014185
Briciclib (ON 014185) is a eukaryotic translation initiation factor 4E (eIF4E) inhibitor. Briciclib exhibits broad-spectrum anti-cancer activity, including in mantle cell leukemia, breast cancer, gastric cancer, and esophageal cancer cells. Briciclib reduces the expression of cyclin D1 and c-Myc, and enhances the expression of P53 and Cleaved Caspase 3 pro-apoptotic proteins. Briciclib can be used for the study of hematological system tumors and solid tumors .
Cat. No.: HY-19831A
CAS No.: 901787-88-0
Research Areas:  

Cancer

(Z)-4EGI-1 is the Z-isomer of 4EGI-1 and is an inhibitor of eIF4E/eIF4G interaction and of translation initiation. (Z)-4EGI-1 effectively binds to eIF4E with an IC50 of 43.5 μM and a Kd value of 8.74 μM. (Z)-4EGI-1 has anticancer activity .
Cat. No.: HY-RS04274
Research Areas:  

Others

EIF4E Human Pre-designed siRNA Set A contains three designed siRNAs for EIF4E gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.: HY-119271
CAS No.: 256497-58-2
Purity:  99.11%
Synonyms: SDS-1-021
Target:  

c-Myc Apoptosis

Research Areas:  

Cancer

CMLD010509 (SDS-1-021) is a highly specific inhibitor of the oncogenic translation program supporting multiple myeloma (MM)-including key oncoproteins such as MYC, MDM2, CCND1, MAF, and MCL-1. CMLD010509 (SDS-1-021) shows an IC50 below 10 nM for most MM cell lines and induces apoptosis. CMLD010509 (SDS-1-021) is a potent and selective translation inhibitor through an eIF4E phosphorylation-independent mechanism .
Cat. No.: HY-176428
CAS No.: 3120743-91-8
Synonyms: P11-2
PROTAC MNK1 degrader-1 is a selective MNK1 PROTAC degrader with a DC50 of 11.92 nM, and a Dmax > 96% in MV4-11 cells. PROTAC MNK1 degrader-1 significantly reduces p-eIF4E (IC50: 22.07 nM), induces apoptosis, and arrests the cell cycle at the G1 phase. PROTAC MNK1 degrader-1 has potent antitumor activity. PROTAC MNK1 degrader-1 has robust antileukemic efficacy in MV4-11 xenograft mice model with acceptable drug safety .
Cat. No.: HY-145309
CAS No.: 2573979-29-8
Research Areas:  

Cancer

eIF4E-IN-3 (Example 485) is a eIF4E inhibitor with an IC50 of 0.00859 μM. eIF4E-IN-3 inhibits the activity of eIF4E. eIF4E-IN-3 is used in cancer research .
Cat. No.: HY-146805
CAS No.: 42951-68-8
Purity:  99.91%
Research Areas:  

Cancer

EB1 is the inhibitor of kinases MNK with IC50s of 0.69 μM (MNK1) and 9.4 μM (MNK2). EB1 selectively inhibits the growth of cancer cells, but not normal cells. EB1 also increases cell apoptosis and suppresses eIF4E phosphorylation .
Cat. No.: HY-145969
CAS No.: 1093268-63-3
Synonyms: 3'-O-Me-m7G(5')ppp(5')G
β-S-ARCA (3'-O-Me-m7G(5')ppp(5')G) is a mRNA 7-methylguanosine (m7G) cap analog carrying a phosphorothioate (PS) moiety. β-S-ARCA binds eIF4E via electrostatic interactions between its β-sulfur atom and positively charged Arg and Lys residues in the protein binding site. β-S-ARCA prevents the decapping by Dcp2, increases the mRNA half-life, enhances cap-dependent translation, and increases protein expression in cells. β-S-ARCA has been applied in researching experimental mRNA-based anticancer vaccines .
Cat. No.: HY-159059
Purity:  41.20%
Ganoderma Lucidum/Reishi Extract is a Ganoderma lucidum extract. Ganoderma Lucidum/Reishi Extract reduces the expression of c-Myc, BCL-2, BCL-XL, TERT, PDGFB, eIF4G, Survivin, β-catenin, and eIF4E. Ganoderma Lucidum/Reishi Extract downregulates the gene expression of MMP-9. Ganoderma Lucidum/Reishi Extract upregulates the expression of IL8. Ganoderma Lucidum/Reishi Extract is applicable to the research of inflammatory breast cancer. Ganoderma Lucidum is used in the research of various diseases, such as allergy, arthritis, hypertension, neurasthenia, inflammation, and cancer .
Cat. No.: HY-145969A
Purity:  99.48%
Synonyms: 3’-O-Me-m7G(5')ppp(5')G triammonium
β-S-ARCA (3'-O-Me-m7G(5')ppp(5')G) triammonium is a mRNA 7-methylguanosine (m7G) cap analog carrying a phosphorothioate (PS) moiety. β-S-ARCA triammonium binds eIF4E via electrostatic interactions between its β-sulfur atom and positively charged Arg and Lys residues in the protein binding site. β-S-ARCA triammonium prevents the decapping by Dcp2, increases the mRNA half-life, enhances cap-dependent translation, and increases protein expression in cells. β-S-ARCA triammonium has been applied in researching experimental mRNA-based anticancer vaccines .
Cat. No.: HY-114267
CAS No.: 1884710-81-9
Purity:  ≥98.0%
Target:  

mTOR

Research Areas:  

Others

Cbz-B3A is a potent and selective inhibitor of mTORC1 signaling that appear to bind to ubiquilins 1, 2, and 4, and Cbz-B3A inhibits the phosphorylation of eIF4E-binding protein 1 (4EBP1).
Cat. No.: HY-139098
CAS No.: 62828-64-2
Synonyms: m7Gp3G
7-Methyl-diguanosine triphosphate (m7Gp3G) is an mRNA cap structure analog that inhibits in vitro protein synthesis by binding to the translation initiation complex. 7-Methyl-diguanosine triphosphate binds to eIF4E, promotes cap-dependent translation initiation, stabilizes mRNA, and acts as a translation enhancer. 7-Methyl-diguanosine triphosphate can be used to prepare synthetic capped RNA transcripts for studies related to mRNA translation, splicing, turnover, and intracellular transport .
Cat. No.: HY-145240
CAS No.: 2573979-31-2
Research Areas:  

Infection Cancer

eIF4E-IN-1 is a potent inhibitor of eIF4E. eIF4E-IN-1 inhibits immunosuppression components such as immune checkpoint proteins PD-1, PD-L1, LAG3, TIM3, and/or IDO, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease (extracted from patent WO2021003194A1, compound Y) .